ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

S Paluch-Shimon¹, F Cardoso², A H Partridge³, O Abulkhair⁴, H A Azim⁵, G Bianchi-Micheli⁶, M J Cardoso², G Curigliano⁷, K A Gelmon⁸, O Gentilini⁹, N Harbeck¹⁰, B Kaufman¹¹, S B Kim¹², Q Liu¹³, J Merschdorf¹⁴, P Poortmans¹⁵, G Pruneri¹⁶, E Senkus¹⁷, B Sirohi¹⁸, T Spanic¹⁹, V Sulosaari²⁰, F Peccatori²¹, O Pagani²²

Affiliations

¹ Hadassah University Hospital & Faculty of Medicine, Hebrew University, Jerusalem, Israel. Electronic address: shanipal@hadassah.org.il.
² Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
³ Dana-Farber Cancer Institute, Boston, USA.
⁴ King Abdulaziz Medical City for National Guard, Riyadh, Saudi Arabia.
⁵ Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico.
⁶ Breast Unit of Southern Switzerland, Lugano, Switzerland.
⁷ European Institute of Oncology IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
⁸ British Columbia Cancer, Vancouver, Canada.
⁹ San Raffaele Hospital, Milan, Italy.
¹⁰ Breast Center, Department of OB&GYN and CCCMunich, LMU University Hospital, Munich, Germany.
¹¹ Sheba Medical Center, Ramat Gan, Israel.
¹² Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
¹³ Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
¹⁴ Young Survival Coalition, New York, USA.
¹⁵ Iridium Netwerk, Department of Radiation Oncology & University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium.
¹⁶ National Cancer Institute, IRCCS Foundation, Milan, Italy.
¹⁷ Medical University of Gdansk, Gdansk, Poland.
¹⁸ Max Institute of Cancer Care, New Delhi and Gurgaon, India.
¹⁹ Europa Donna Slovenia, Ljubljana, Slovenia.
²⁰ European Oncology Nursing Society (EONS) and Turku University of Applied Sciences, Turku, Finland.
²¹ European Institute of Oncology IRCCS, Milan; European Institute of Oncology IRCCS & European School of Oncology, Milan, Italy.
²² Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Vaud, Geneva University Hospitals, Lugano University, Swiss Group for Clinical Cancer Research (SAKK), Lugano, Switzerland.

PMID: 35934170
DOI: 10.1016/j.annonc.2022.07.007

Free article

Practice Guideline

ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

S Paluch-Shimon et al. Ann Oncol. 2022 Nov.

Free article

. 2022 Nov;33(11):1097-1118.

doi: 10.1016/j.annonc.2022.07.007. Epub 2022 Aug 4.

Authors

Affiliations

¹ Hadassah University Hospital & Faculty of Medicine, Hebrew University, Jerusalem, Israel. Electronic address: shanipal@hadassah.org.il.
² Breast Unit, Champalimaud Clinical Centre/Champalimaud Foundation, Lisbon, Portugal.
³ Dana-Farber Cancer Institute, Boston, USA.
⁴ King Abdulaziz Medical City for National Guard, Riyadh, Saudi Arabia.
⁵ Breast Cancer Center, Hospital Zambrano Hellion, Tecnologico de Monterrey, San Pedro Garza Garcia, Nuevo Leon, Mexico.
⁶ Breast Unit of Southern Switzerland, Lugano, Switzerland.
⁷ European Institute of Oncology IRCCS, Milan; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
⁸ British Columbia Cancer, Vancouver, Canada.
⁹ San Raffaele Hospital, Milan, Italy.
¹⁰ Breast Center, Department of OB&GYN and CCCMunich, LMU University Hospital, Munich, Germany.
¹¹ Sheba Medical Center, Ramat Gan, Israel.
¹² Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
¹³ Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
¹⁴ Young Survival Coalition, New York, USA.
¹⁵ Iridium Netwerk, Department of Radiation Oncology & University of Antwerp, Faculty of Medicine and Health Sciences, Wilrijk-Antwerp, Belgium.
¹⁶ National Cancer Institute, IRCCS Foundation, Milan, Italy.
¹⁷ Medical University of Gdansk, Gdansk, Poland.
¹⁸ Max Institute of Cancer Care, New Delhi and Gurgaon, India.
¹⁹ Europa Donna Slovenia, Ljubljana, Slovenia.
²⁰ European Oncology Nursing Society (EONS) and Turku University of Applied Sciences, Turku, Finland.
²¹ European Institute of Oncology IRCCS, Milan; European Institute of Oncology IRCCS & European School of Oncology, Milan, Italy.
²² Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz, Vaud, Geneva University Hospitals, Lugano University, Swiss Group for Clinical Cancer Research (SAKK), Lugano, Switzerland.

PMID: 35934170
DOI: 10.1016/j.annonc.2022.07.007

Abstract

We dedicate this manuscript in memory of a dear friend and colleague Bella Kaufman. The fifth International Consensus Symposium for Breast Cancer in Young Women (BCY5) took place virtually in October 2020, organized by the European School of Oncology (ESO) and the European Society of Medical Oncology (ESMO). Consensus recommendations for the management of breast cancer in young women were updated from BCY4 with incorporation of new evidence to inform the guidelines. Areas of research priorities as well as specificities in different geographic and minority populations were identified. This manuscript summarizes the ESO-ESMO international consensus recommendations, which are also endorsed by the European Society of Breast Specialists (EUSOMA).

Keywords: breast cancer; fertility; young women.

PubMed Disclaimer

Conflict of interest statement

Disclosure SPS: Advisory Board consultancy, speaker's bureau: AstraZeneca, Pfizer, Novartis, Lilly, Roche, MSD, Exact Sciences. Research Funding: Pfizer. HAA: Recipient of grants/research supports: Amgen. Recipient of honoraria or consultation fees: Novartis, Roche. Employment: Pierre Fabre. FC: Recipient of honoraria or consultation fees: Amgen, Astellas/Medivation, AstraZeneca, Celgene, Daiichi-Sankyo, Eisai, GE Oncology, Genentech, GlaxoSmithKline, Macrogenics, Medscape, Merck-Sharp, Merus BV, Mylan, Mundipharma, Novartis, Pfizer, Pierre-Fabre, prIME Oncology, Roche, Samsung Bioepis. GC: Recipient of grants/research supports: Merck, Astra Zeneca. Recipient of honoraria or consultation fees: Daichii Sankyo. Participation in a sponsored speakers’ bureau: Novartis, Pfizer, Lilly. KAG: Recipient of grants/research supports: Pfizer, Astra Zeneca. Recipient of honoraria or consultation fees: Pfizer, Lilly, Astrazeneca, Novartis, Mylan, Benentech, Merck, Roche, Nanostring. NH: Honoraria for lectures and/or consulting from Amgen, Astra Zeneca, Daiichi-Sankyo, Exact Sciences, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, Sandoz, Seagen (all outside the submitted work). SBK: Research funding from Novartis, Sanofi-Aventis and DongKook Pharm Co; consultant in advisory boards—Novartis, AstraZeneca, Lilly, Dae Hwa Pharmaceutical Co. Ltd, ISU Abxis, Daiichi-Sankyo and Beigene; and stocks—Genopeaks, NeogeneTC (all outside the submitted work). FP: Recipient of honoraria or consultation fees: Roche Diagnostics, Ipsen, Merck (all outside the submitted work). ES: Recipient of grants/research supports: Amgen, AstraZeneca, Boehringer, Eli Lilly, Merck, Novartis, Pfizer, Roche, Samsung. Recipient of honoraria or consultation fees: Amgen, AstraZeneca, Clinigen, Egis, Eli Lilly, Genomic Health, Novartis, Pfizer, Pierre Fabre, Roche, Sandoz, TLC Biopharmaceuticals. Travel support: Amgen, AstraZeneca, Egis, Novartis, Pfizer, Roche. All other authors have declared no conflicts of interest.

Cited by

Global burden and attributable risk factors of breast cancer in young women: historical trends from 1990 to 2019 and forecasts to 2030 by sociodemographic index regions and countries.
Yuan M, Zhu Y, Ren Y, Chen L, Dai X, Wang Y, Huang Y, Wang H. Yuan M, et al. J Glob Health. 2024 Jul 19;14:04142. doi: 10.7189/jogh.14.04142. J Glob Health. 2024. PMID: 39026460 Free PMC article.
Dose Volume and Liver Function Test Relationship following Radiotheraphy for Right Breast Cancer: A Multicenter Study.
Güzelöz Z, Ayrancıoğlu O, Aktürk N, Güneş M, Alıcıkuş ZA. Güzelöz Z, et al. Curr Oncol. 2023 Sep 26;30(10):8763-8773. doi: 10.3390/curroncol30100632. Curr Oncol. 2023. PMID: 37887532 Free PMC article.
A nomogram for predicting breast cancer based on hematologic and ultrasound parameters.
Liu Y, Zhu H, Yuan J, Wu G. Liu Y, et al. Am J Transl Res. 2023 Sep 15;15(9):5602-5612. eCollection 2023. Am J Transl Res. 2023. PMID: 37854218 Free PMC article.
Latent profiles of ambivalence over emotional expression in young breast cancer patients: A cross-sectional study.
Chen X, Wang Z, Wang S, Zhang F, Li X, Zhao J. Chen X, et al. Int J Nurs Sci. 2025 Jun 16;12(4):379-385. doi: 10.1016/j.ijnss.2025.06.005. eCollection 2025 Jul. Int J Nurs Sci. 2025. PMID: 40786852 Free PMC article.
Prognostic nomograms for young breast cancer: A retrospective study based on the SEER and METABRIC databases.
Li Y, Tao X, Ye Y, Tang Y, Xu Z, Tian Y, Liu Z, Zhao J. Li Y, et al. Cancer Innov. 2024 Oct 25;3(6):e152. doi: 10.1002/cai2.152. eCollection 2024 Dec. Cancer Innov. 2024. PMID: 39464427 Free PMC article. Review.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

Affiliations

ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical